High quality of care is most desired when balanced with cost-effectiveness. Although early identification of the bleeding source of LGIB is desired by many health-care providers, outcomes may not be altered by early endoscopic interventions as shown by two randomized trials. [4, 5] Unlike upper GI bleed, very few studies were done to help triage the patients presenting to the hospital with chief complaint of LGIB. The challenges stem from the variety of the causes of LGIB with different morbidity and mortality rates. The initial clinical presentation may not correlate with the severity of LGIB as shown in previous studies aimed to determine the predictors of poor outcomes. Although the incidence of LGIB is increased with the use of anti-thrombotic (AT) medications (including antiplatelet [Plt] and anticoagulant medications), the severity of LGIB and the need of surgical interventions in patients taking AT medications is not well defined. [6] [7] [8] The use of AT medication in combination have been on the rise. To further evaluate the risks of these medications, we collected clinical data retrospectively from a cohort of patients using the above-mentioned medications admitted to our institution for LGIB with a goal of evaluating the risk of severe bleeding.
Methods

Study design
A retrospective cohort study of the records of the patients admitted to St. Joseph Regional Medical Center from January 1, 2009, to December 31, 2011, was evaluated. All the patients included were admitted through the emergency department with complaints of or relating to LGIB. The study was approved by the institutional review board of the hospital.
Subject selection
A total of 3436 subjects were selected for review using International Classification of Diseases, Ninth Revision codes representing various etiologies of LGIB. Once a master participant list was compiled, all personal patient information was removed and subjects were assigned independent identification numbers that correlated electronic medical record files. A solitary copy of this master list was held by the lead investigator solely for reference, as needed, to ensure patient confidentiality and observer objectivity. The electronic records of these patients were reviewed, and patients were excluded from the study if any evidence of upper GI bleed was found on the admission report, emergency room record, upper gastroduodenoscopy report, nasogastric aspirate, nuclear or angiographic studies. Additional exclusion criteria included: low grade bleeding (scant blood on toilet tissue only or positive tests of occult blood stool cards), patients transferred from other acute care facilities, hospitalized patients for a different complaint, or populations younger than 18 years of age. Ultimately, 511 met the inclusion criteria and were incorporated into our study.
Studied variables
Once included, patients' electronic charts were reviewed to include a total of 19 variables obtained from history and physical examination reports, laboratory transcripts and procedural reports. Variables were: age, sex, ethnicity, daily use aspirin of any dose, daily use of clopidogrel, use of nonsteroidal anti-inflammatory drugs (NSAIDs) at least twice in the last week prior to admission, the daily use of anticoagulants (warfarin, heparin), stool color, the presence of presyncope or syncope, encephalopathy, the presence of abdominal pain, heart rate (HR) and systolic blood pressure (SBP), abdominal tenderness, gross blood on rectal examination, Acute Physiologic Assessment and Chronic Health Evaluation (APACHE) II severity index, Plt count, and international normalized ratio (INR). Our data were documented on subject specific, individual data collection forms identifiable only by the assigned independent identification numbers, to be entered into our database.
Outcomes
The primary outcome studied was severe LGIB as defined by the requirement of at least two units of packed red blood cells and/or a decrease in the hematocrit (Hct) of 20% or more or recurrent bleeding after 24 h of clinical stability with additional transfusions required. Other outcomes included surgical intervention. The initial recorded Hct was considered baseline as compared to the lowest Hct level in the following 24 h. Same rule was applied to the recurrent bleeding when measuring Hct before the recurrence of LGIB (baseline Hct) and compare it to the lowest Hct level in the next 24 h.
Statistical methods
Univariate analysis using t-test on continuous variables and Chi-square test on categorical variables were done before carrying out logistic regression analysis. Logistic regression analyses were conducted to measures of association between the variables and LGIB. Logistic regression analysis was not carried for surgical intervention and death because none of the variables was significant from univariate tests.
Results
There were statistically significant association of age <65 years, sex, white and hispanic ethnicities, aspirin use (−), NSAID, warfarin, hep/lovenox (+), acetylsalicylic acid (ASA) + plavix, ASA + warfarin, ASA alone with LGIB. Furthermore, anticoagulation or anti-Plt (no anticoagulation/ Plt, (+) anticoagulation/Plt, ASA alone), stool color (red/bloody and dark/melena), history of abdominal pain, AM/PM, weekend, onset to ED (≤1 day, 2 days, and 2-7 days), HR (HR <90), SBP, abdominal tenderness, bright red blood, Plts (Plt >50), and INR were associated with LGIB [ Table 1 ].
Multivariate analysis
Eight variables were significant at P = 0.05 from logistic regression analysis. The logistic regression coefficients are presented in Tables 2, 3 , and Figure 1 . Odd ratios (ORs) were calculated using only variables that were significant, and are presented in Table 4 . We can see that the ORs of stool color, Contd... lightheadedness/syncope, gross blood on rectal, APACHE II, and PT are >1. This means that these variables are associated with higher odds of LGIB. The odds ratio of abdominal tenderness on examination is <1, and this would suggest that abdominal tenderness on examination is associated with lower odds of LGIB. The results also revealed that HR and Plt count have no association with risk of LGIB because their ORs are equal to 1.
dIscussIon
The use of dual anti-Plt therapy after percutaneous coronary intervention with drug-eluting stents has been used in 1.2 million patients yearly in the United States of America. [9] [10] [11] [12] [13] [14] [15] The use of NSAIDs, aspirin and/or clopidogrel are commonly prescribed and have been associated with increased overall GI bleeding risk; some studies suggested that the risk of GI bleed even higher when the above medications are used in combination. [9, 10] Heparin and vitamin K antagonist, namely, warfarin, both increase the risk and incidence of bleed, especially the GI bleed, shown to be the most common major and fatal cause of bleeding in bleed in a previous studies. [11] The incidence of GI bleeding is not uncommon, up to 2.7% reported in a previous study with most of bleeding events occur early in the first 30 days of therapy. Especially those at high risk for bleeding such as patients with previous history of GI bleed, peptic ulcer bleed, untreated Helicobacter pylori infection, intestinal polyps, or cancer. [12] [13] [14] [15] In addition, the incidence of lower intestinal bleeding (LIB), especially diverticular bleed, was also found to be increased in patients taking antithrombotic medication. [16] [17] [18] While many studies examine the risk for generalized intestinal bleeding and the overall incidence related to anti-Plt therapy, very few explore the growing population of patients on dual anti-Plt treatment, and to elucidate the incidence of severe LIB and the risks associated. [7] [8] [9] [10] [11] [12] [13] [14] [15] Having been identified as a risk factor for generalized bleeding, it is important to stratify and consider seriousness of bleeding episodes associated with dual anti-Plt therapy. In our study, a total of 511 patients were found to have true lower intestinal bleeding. Among these subjects 61 were shown to be on dual or multiple AT therapies. Further exploration revealed that while use of multiple blood thinning agents may in fact pose a significant risk to overall LIB, it did not significantly increase the risk for severe bleeding as outlined above. The need for surgical intervention was documented in 28 patients (5.47%), and death was encountered in six patients (1.17%). This information is not only useful with regards to triage and early intervention, but as a cost-effective measure to delineate which patients will benefit from early endoscopy and those that will not.
Although the incidence of GI bleed is increased in patients taking the anti-Plt medications or the anticoagulants, the predictors of severe LGIB in patients taking the above-mentioned medications have rarely been studied. [17] The early recognition of patients at high risk of severe LGIB is of most importance due to increased risk of complication and surgical intervention. Although still debatable, colonoscopy within 24 h of admission does not necessarily change the outcomes. [4, 5, 13] The exception is in selected cases, mainly in diverticular bleeds, where early colonoscopy with endoscopic interventions (epinephrine injection, clipping, and/or endoscopic band ligation) may be an option to control the LGIB and locate the bleeding site to help minimize surgical resection if needed during the hospital course. [14] This study represents a greater understanding and perspective on a common GI disease complication that is greatly affected by increased patient exposure to AT agents. There is limited data in the academic literature regarding outcomes of patients on novel AT agents, especially in the growing incidence of polypharmacy. This investigation provides significant evidence within a substantial cohort of subjects on dual anti-Plt therapies. These findings, while meaningful may need to be replicated and enhanced by a larger patient sample size. The study is also limited by its retrospective nature, inability to control confounding variables, and inadequacy of medication exposure data (duration of exposure, dosing, and compliance) as is the concern in any analysis of medication exposure. As the pool of data expands and additional agents are employed for effective AT treatment, there will certainly be a need for future analysis of multiple drug-drug interactions and their association with adverse events, desired outcomes, and risk stratification. In the future, further data, ideally from randomized trials are needed to better identify and manage the effects of dual anti-Plt therapy, with and without warfarin or the newer antithrombotic agents currently in use, and the optimal duration of anti-Plt therapy among different risk subgroups.
conclusIon
Our study found that the use of multiple blood thinners does not significantly increase the risk for severe LGIB. Even though risk factors such as old age, intensity of anti-Plt use and or anticoagulation, race, sex, presence of abdominal pain, etc., may, in fact, pose a significant risk to overall LGIB, they did not significantly increase the risk of severity of the LGIB. To decrease the risk of LGIB while maintaining the effect of anticoagulation, we recommend close follow-ups, frequent monitoring of INR values and a strategy of low to moderate intensity of anticoagulation and or anti-Plt use could be considered in patients with many risk factors of LGIB.
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